Phillip Minar
Pediatric GI, Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (18)
Year:
2026
Background Antibiotics are widely used for perianal fistulising complications (PFC) of Crohn’s disease (CD). We sought to characterize antibiotic use for PFCs in a multicentre cohort of paediatric patients with CD. We hypothesized prolonged antibiotic therapy would not improve healing or reduce recurrence. Methods We conducted a retrospective study at 7 US paediatric sites. Patients (age 2-21yr) with new PFC from CD (1/1/2014–31/12/2019), and minimum 3 yr follow-up were included. PFC was defined as perianal/perirectal abscess and/or fistula. Antibiotic exposure was measured from PFC diagnosis through 3 yr; duration was calculated from all prescriptions by start-day and quantity dispensed. The primary outcome was any documented PFC healing within 1 yr. Secondary outcomes were PFC healing by imaging, and PFC recurrence. Analyses included chi-square, Kruskal-Wallis, and logistic regression. Results 291 patients with PFC were included (Table 1). 80 (27%) had abscess on imaging or exam, and 53 (66%) had drainage/seton procedure within 90 days. Antibiotics were used by 88% of those with and 70% of those without abscess (p = 0.002). Among those with abscess, 91% with and 81% without antibiotics had drainage procedures (p = 0.25). Antibiotic prescriptions over 3 yr ranged from 0-33 per patient: median cumulative duration 89 days (interquartile range [IQR] 36-236). 153 (53%) had PFC healing within 1 yr: 24 (16%) by symptom resolution alone, 90 (59%) on exam, 37 (24%) by imaging. 65% started anti-tumour necrosis factor (TNF) medications within 90 days. Healing by 1 yr was similar for those treated with and without antibiotics (56% vs 44%; p = 0.084). Healing was the same with and without abscess (57% vs 50%; p = 0.23), and among those with abscess the same with and without antibiotics (57% vs. 55%; p = 0.87). When requiring imaging (N = 125), there was no difference in antibiotic duration between those with and without healing (median 152, IQR 69-298 vs. 87, IQR 31-256; p = 0.103). In adjusted analyses (Table 2), duration of antibiotic use was not associated with PFC healing, but early anti-TNF improved odds of healing. Among all with PFC healing by 1 yr (N = 153), 38 (25%) developed recurrent PFCs. More antibiotics for 1st PFC was associated with PFC recurrence (median 108 days, IQR 35-369 vs no recurrence 30, IQR 0-114; p = 0.001). Conclusion Children with PFC on average received ∼3 mo antibiotics, yet there was no difference in PFC healing associated with duration. Prolonged antibiotic use may reflect severity. These findings may suggest limited benefit of prolonged antibiotic therapy for PFC healing in CD. Further studies must address patient symptoms and QOL to guide treatment decisions. Conflict of interest: Prof. Dr. Adler, Jeremy: My institution has received grant funding from the Agency for Healthcare Research and Quality to fund this current research, and grant funding from Janssen Research & Development LLC for studies of the SEMA-CD colonoscopy score. I have received no personal funding. Tribble, Alison: Grant funding to my institution from the Agency for Healthcare Research and Quality (AHRQ) to fund this current research. Grant from the Cystic Fibrosis Foundation. Grant support from another AHRQ grant. McDonnell, Erin: No conflict of interest Chavannes, Mallory: Grant funding to my institution from the Agency for Healthcare Research and Quality to fund this current research. I have a CDA from the Robert A Winn Foundations, which funding partially comes from a collaboration between the VCU Foundation and the BMS Foundation. I receive consultation fees from CapsoVision Inc. Egberg, Matthew: Grant funding to my institution from the Agency for Healthcare Research and Quality to fund this current research. Kandavel, Prashanthi: Grant funding to my institution from the Agency for Healthcare Research and Quality to fund this current research. Maltz, Ross: Grant funding to my institution from the Agency for Healthcare Research and
Year:
2026
Year:
2026
Year:
2026
Background Ostomies may facilitate healing of perianal fistulising complications (PFC) of Crohn’s disease (CD). The frequency of creating and closing ostomies has not been well characterised in paediatric CD. We described ostomy use in a multicentre cohort. and hypothesized that risk of ostomy differs by PFC timing. PFC before CD diagnosis may be associated with access to care, while later PFC may reflect treatment patterns. Methods We conducted a retrospective review at 7 US paediatric sites. Patients (ages 2-21 yr) with new PFC from CD (1/1/2014–31/12/2019) were included. PFC was defined as perianal abscess and/or fistula. PFC timing was defined as: 1) Before/At CD if identified before or < 30 days after CD diagnosis, or 2) After CD if ≥ 30 days after CD diagnosis. Analyses included Student t-test, Kruskal-Wallis, and logistic regression. Results Of 291 patients with PFCs, 186 (64%) developed PFC Before/At CD, and 95 (33%) After CD. Overall, 36 (12.4%) underwent ostomy, more commonly if PFC developed After CD (23/95, 24.2%) than if developed Before/At CD (11/186, 5.9%; p < 0.001) (10 dates were missing). In adjusted analysis (Table 1), ostomy was 3x more common among female patients. Patients with PFC After CD who did not have commercial insurance had the highest odds of ostomy, >5x more than those with PFC Before/At CD with commercial insurance (Figure 1). Of the 36 patients who underwent ostomy creation, 28 (78%) had their ostomy closed after median 371 days (interquartile range [IQR] 199-799), among whom 3 (10%) had a 2nd ostomy. In total 11 (including all 3 with 2ndostomy) had an ostomy through the end of the 3-yr study period (31% of all with ostomy, 3.8% of all with PFC) with a median 1043 days from ostomy creation to study end (IQR 812-1204). It is not clear how many, if any, had ostomy closure after study end. Among the 25 who had successful ostomy closure, the median days to closure was 350 (IQR 201-665). There was no difference in ostomy closure by race (p = 0.53) or timing of PFC (p = 0.11). However, commercial insurance was associated with shorter median time to ostomy closure 342 days (IQR 77-513) compared to those without commercial insurance 530 days (IQR 24-916) for a median difference of 6.3 months (p = 0.045). Conclusion Among children with CD and PFC in a multicentre retrospective cohort, 12% had an ostomy created, among whom nearly 30% ultimately required years-long ostomy. Lack of commercial insurance and developing PFC after diagnosis were associated with 5-fold increased odds of ostomy, likely reflecting barriers to care. Strategies to prevent PFC and reduce the need for ostomy, through earlier access, and optimised medical therapy are needed. Conflict of interest: Gadepalli, Samir: none Manning, Lauren: Grant funding to my institution from the Agency for Healthcare Research and Quality to fund this current research McMahon, Lisa: Grant funding to my institution from the Agency for Healthcare Research and Quality to fund this current research Mollen, Kevin: Grant funding to my institution from the Agency for Healthcare Research and Quality to fund this current research Nwomeh, Benedict: Grant funding to my institution from the Agency for Healthcare Research and Quality to fund this current research Phillips, Michael: Grant funding to my institution from the Agency for Healthcare Research and Quality to fund this current research Gayer, Christopher: Grant funding to my institution from the Agency for Healthcare Research and Quality to fund this current research Chavannes, Mallory: Grant funding to my institution from the Agency for Healthcare Research and Quality to fund this current research. I have a CDA from the Robert A Winn Foundations, which funding partially comes from a collaboration between the VCU Foundation and the BMS Foundation. I receive consultation fees from CapsoVision Inc. Egberg, Matthew: Grant funding to my institution from the Agency for Healthcare Research and Quality to f
Year:
2026
Year:
2026
Year:
2026
INTRODUCTION: Human leukocyte antigen (HLA) DQA1*05 has been associated with the development of anti-drug antibodies (ADA) to tumor necrosis factor antagonists (anti-TNFα) and treatment failure among adults with Crohn's disease (CD). However, findings from other studies have been inconsistent with limited pediatric data. METHODS: We analyzed banked serum from patients with CD aged <21 years enrolled in clinical outcomes of Methotrexate Binary Therapy in practice, a multicenter, prospective randomized trial of anti-TNFα monotherapy vs combination with methotrexate. The primary outcome was a composite of factors indicative of treatment failure. The secondary outcome was ADA development. RESULTS: A trend toward increased treatment failure among HLA DQA1*05-positive participants was not significant (hazard ratio 1.58, 95% confidence interval [CI] 0.95–2.62; P = 0.08). After stratification by HLA DQA1*05 and by methotrexate vs placebo, patients who were HLA DQA1*05 negative and assigned to methotrexate experienced less treatment failures than HLA DQA1*05-positive patients on placebo (hazard ratio 0.31, 95% CI 0.13–0.70; P = 0.005). A trend toward increased ADA development among HLA DQA1*05-positive participants was not significant (odds ratio 1.96, 95% CI 0.90–4.31, P = 0.09). After further stratification, HLA DQA1*05-negative participants assigned to methotrexate were less likely to develop ADA relative to HLA DQA1*05-positive patients on placebo (odds ratio 0.12, 95% CI 0.03–0.55; P = 0.008). DISCUSSION: In a randomized trial of children with CD initiating anti-TNFα, 40% were HLA DQ-A1*05 positive, which was associated with a trend toward increased risk of both treatment failure and ADA. These risks were mitigated, but not eliminated, by adding oral methotrexate. HLA DQ-A1*05 is an important biomarker for prognosis and risk stratification.
Year:
2025
Background We previously identified circulating and MRI biomarkers associated with the surgical management of Crohn’s disease (CD). Here we tested associations between these biomarkers and ileal resection inflammation and collagen content. Methods Fifty CD patients undergoing ileal resection were prospectively enrolled at 4 centers. Circulating CD64, extracellular matrix protein 1 (ECM1), GM-CSF autoantibodies (GM-CSF Ab), and fecal calprotectin were measured by ELISA. Ileal 3-dimensional magnetization transfer ratio (3D MTR), modified Look-Locker inversion recovery (MOLLI) T1 relaxation, diffusion-weighted intravoxel incoherent motion (IVIM), and the simplified magnetic resonance index of activity (sMaRIA) were measured by MRI. Ileal resection specimen acute inflammation was graded, and collagen content was measured quantitatively using second harmonic imaging microscopy. Associations between biomarkers and ileal collagen content were tested. Results Median (interquartile range [IQR]) age was 19.5 (16-33) years. We observed an inverse relationship between ileal acute inflammation and collagen content (r = −0.39 [95% confidence interval {CI}: −0.61, −0.10], P = .008). Most patients (33 [66%]) received biologics, with no variation in collagen content with treatment exposures. In the univariate analysis, CD64, GM-CSF Ab, fecal calprotectin, and sMaRIA were positively associated with acute inflammation and negatively associated with collagen content (P < .1). The multivariable model for ileal collagen content (R2 = 0.31 [95% CI: 0.11, 0.52]) included log CD64 (β = −.27; P = .19), log ECM1 (β = .47; P = .06), log GM-CSF Ab (β = −.15; P = .01), IVIM f (β = .29, P = .10), and IVIM D* (β = 1.69, P = .13). Conclusions Clinically available and exploratory circulating and MRI biomarkers are associated with the degree of inflammation versus fibrosis in CD ileal resections. With further validation, these biomarkers may be used to guide medical and surgical decision-making for refractory CD.
Year:
2025
Objectives Pediatric acute pancreatitis (AP) is associated with gut dysbiosis. We aimed to determine if dysbiosis persisted during follow‐up and whether it is associated with clinical outcomes. Methods Prospective enrollment of participants <21 years with first AP. Stool samples were obtained at baseline ( n = 41), 3 months ( n = 19), and 12 months ( n = 12) and in healthy controls (HC; n = 34). Evaluation for diabetes (DM) or prediabetes (pre‐DM) was performed. At 12‐month follow‐up gastrointestinal (GI) symptom surveys were completed and AP recurrence‐acute recurrent pancreatitis (ARP) recorded. Shotgun metagenomic sequencing was performed on extracted microbial DNA. Results Microbial alpha diversity was lower for AP versus HC at all three time points ( p < 0.008). Bray‐Curtis ordinations showed the AP cohort did not cluster by time point, highlighting similarity in microbial composition over time. Within 12‐month follow‐up: 7/44 participants developed pre‐DM/DM, 7/42 developed ARP, 16 had zero or one while 15 had multiple GI symptoms. Distinct clustering of samples was observed in the baseline samples of the group that developed ARP ( p = 0.023) and in follow‐up samples with multiple GI symptoms, p < 0.05. Relative abundance of most species was lower in AP samples when compared to HC at all time points with enrichment in Ruminococcus gnavus and Clostridium innocuum (AQ) (False Discovery Rate p < 0.05). Several pathways involved in protein biosynthesis were depleted in the AP cohort at all time points. Conclusions Gut dysbiosis persisted following AP in children at 3 and 12 months follow‐up compared to HC. Microbiome signatures differed in the ARP cohort and those with multiple GI symptoms.
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Collaborators (10)
Ruben Colman
MD, PhD; Assistant Professor of Pediatrics; Pediatric Gastroenterologist
Stanford University
Jonathan Dillman
department of pediatrics university of cincinnati college of medicine cincinnati ohio usa
Faizan Ahmed
Staff Scientist
Cincinnati Children's Hospital Medical Center
Alexander J. Towbin
Cincinnati Children's Hospital Medical Center
Johan Van Limbergen
Amsterdam University Medical Centers
Subra Kugathasan
Professor
Emory University
Jeremy Adler
University of Michigan
Dawn Ebach
Clinical Professor
The University of Iowa Roy J and Lucille A Carver College of Medicine
Samir Gadepalli
University of Michigan
Alison Tribble
University of Michigan
Make your next move.
Prepare your application
Review drafts before you send them.